ach year, an estimated 1.25 million pacemakers and 410,000 implantable cardioverter-defibrillators (ICDs) are implanted worldwide. 1 Between 14 and 35% of patients receiving these devices require long-term oral anticoagulation therapy, [2] [3] [4] [5] and their periprocedural treatment presents a dilemma to physicians. This is particularly true for the subset of patients at moderate-to-high risk (≥5% per year) for thromboembolic events. 6 Current guidelines recommend interruption of oral anticoagulation therapy and the use of bridging therapy with intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin around the time of surgery. 6 However, there are a number of potential drawbacks to bridging with heparin in the perioperative period. This approach consumes considerable health care resources. 7 Bridging with heparin also involves a short period of normal coagulability (perhaps even hypercoagulability related to the prothrombotic state of surgery) with an associated risk of thromboembolism. Finally, among patients undergoing pacemaker or ICD surgery, there is a substantial risk of device-pocket hematoma (17 to 31%) when bridging with heparin is used. [8] [9] [10] [11] Device-pocket hematomas can have serious consequences for patients, such as the need for prolonged cessation of all oral anticoagulation therapy with the attendant risk of thromboembolism, 9,12 prolongation of hospitalization, 13 the need for further surgery (e.g., hematoma evacuation), and an increased risk of infection. 14, 15 In response to these issues, some centers have started performing pacemaker and ICD surgery without interruption of anticoagulation therapy with warfarin. 16, 17 However, there have been limited data from clinical trials to support the safety and efficacy of this approach. Two small, randomized trials have been inconclusive. 18, 19 In the first of these trials, device-pocket hematoma developed in 4 of 51 patients (7.8%) in the heparin-bridging group and in 4 of 50 (8.0%) in the continued-warfarin group after implantation. 19 In the second trial, only 7 patients received bridging therapy with heparin. 18 We sought to resolve this dilemma with an adequately powered, randomized clinical trial.
ME THODS

STUDY DESIGN
We conducted the Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial (BRUISE CONTROL) as a multicenter, singleblind, randomized, controlled trial. The trial was designed to determine whether a strategy of continued warfarin treatment at the time of pacemaker or ICD surgery, in patients at moderate-tohigh risk for thromboembolic events, reduces the incidence of clinically significant device-pocket hematoma, as compared with the current standard of practice of bridging with heparin. Full details of the trial design have been published previously. 20 The trial was designed by the steering committee (see the Supplementary Appendix, available with the full text of this article at NEJM.org). The protocol (available at NEJM.org) was approved by the research ethics board at each of the participating centers. The University of Ottawa Heart Institute Cardiovascular Research Methods Centre coordinated the study, collected the data, maintained the database, and performed all the data analyses. All the authors attest to the accuracy and completeness of the reported data, as well as the fidelity of this report to the study protocol. There was no commercial support or involvement in this trial.
PATIENTS
We enrolled patients at 17 centers in Canada and at 1 center in Brazil. 20 In brief, patients were eligible if they had an annual predicted risk of thromboembolism of 5% or more (see the Supplementary Appendix), 21 were taking warfarin, and required nonemergency device (pacemaker or ICD) surgery. Device surgery included implantation of a new device, pulse-generator change, lead replacement, or pocket revision. All patients provided written informed consent.
STUDY PROCEDURES
Eligible patients were randomly assigned in a 1:1 ratio to continued warfarin treatment or bridging therapy with heparin. Randomization was performed with the use of sealed, opaque, serially numbered envelopes and randomly selected block sizes of four to six and was stratified according to clinical center.
In the continued-warfarin group, the international normalized ratio (INR) on the day of surgery was targeted to be 3.0 or lower, except for patients with one or more mechanical valves, for whom an INR of 3.5 or less was permitted. Patients in the heparin-bridging group discontinued warfarin 5 days before the procedure and started receiving full therapeutic doses of lowmolecular-weight heparin or intravenous heparin 3 days before the procedure.
For patients receiving bridging therapy with low-molecular-weight heparin, the final dose was given the morning of the day before the procedure (i.e., >24 hours before the procedure). For patients receiving bridging therapy with intravenous heparin, the infusion was discontinued at least 4 hours before surgery. The administration of heparin was reinitiated 24 hours after the procedure and was continued until a therapeutic INR was achieved. Full details of the heparin-bridging protocol are provided in the Supplementary Appendix.
Clopidogrel was stopped for 5 days before surgery in patients who had undergone implantation of a bare-metal stent more than 1 year previously. Clopidogrel was continued in patients with more recently implanted bare-metal stents and in patients with drug-eluting stents. The timing of reinitiation of clopidogrel therapy after device surgery was at the physician's discretion. Aspirin was continued in all patients.
Patients were aware of the assigned study treatment; blinding was not possible because of the very different nature of the two treatments. To ensure that the investigators were unaware of the study assignments, each center was required to identify two patient-care teams. Each team consisted of one or more research coordinators and one or more physicians. One team had knowledge of the treatment assignments and was responsible for device implantation and follow-up of programming and function but was not allowed any involvement in the evaluation for or management of a device-pocket hematoma. The second team, which had no knowledge of treatment assignments, was responsible for monitoring the surgical wound during the initial hospitalization, at 1 to 2 weeks of follow-up, and during any hospital visits or subsequent admissions and for diagnosing and making all decisions about the management of device-pocket hematomas. Patients in whom a clinically significant hematoma developed were followed until it resolved. Follow-up included monitoring for any additional complications related to the hematoma (e.g., infection).
OUTCOME MEASURES
The primary outcome was clinically significant device-pocket hematoma, defined as a hematoma requiring further surgery, resulting in prolongation of hospitalization, or requiring interruption of oral anticoagulation therapy. Prolongation of hospitalization was defined as extended hospitalization or rehospitalization for at least 24 hours after the index surgical procedure, primarily due to the hematoma. Interruption of anticoagulation therapy was defined as reversal or intentional withholding of oral anticoagulation treatment because of a device-pocket hematoma, resulting in subtherapeutic anticoagulation for at least 24 hours.
Secondary outcomes included each component of the primary outcome, the composite of all other major perioperative bleeding events (hemothorax, cardiac tamponade, or clinically significant pericardial effusion), thromboembolic events (transient ischemic attack, stroke, deep-vein thrombosis, pulmonary embolism, systemic embolism, or valve thrombosis), death from any cause, quality of life, perioperative pain, and patient satisfaction. Details of the assessments of quality of life, pain, and patient satisfaction are provided in the Supplementary Appendix.
STATISTICAL ANALYSIS
We calculated that a sample size of 984 patients would provide 80% power to detect a 30% reduction in the relative risk of the primary outcome in the continued-warfarin group, with the use of a two-sided alpha level of 0.05. We did not expect substantial rates of noncompliance or loss to follow-up. Two interim analyses were planned, when 33% and 66% of the patients had completed followup, with review by an independent data and safety monitoring board. We used a group-sequential method with an O'Brien-Fleming boundary, with P values of 0.0002 and 0.0119 for the first and second interim analyses, respectively.
Descriptive statistics were used for all baseline variables, with means and standard deviations for normally distributed variables, medians and interquartile ranges for nonnormally distributed variables, and rates and proportions for discrete outcomes in each treatment group. Primary and secondary outcomes were compared between treatment groups with the use of the chi-square test. Prespecified subgroup analyses included comparisons of outcomes according to whether patients were taking clopidogrel, whether patients were taking any antiplatelet agent, and whether the planned surgery was for implantation of a new device, a pulse-generator change alone, or a pulse-generator change plus an additional procedure. Analyses were conducted with the use of SAS software, version 9.2 (SAS Institute).
R E SULT S
STUDY PATIENTS
Data on 668 patients were reviewed by the data and safety monitoring board at the second prespecified interim analysis, on February 27, 2013, at which time the board recommended termination of the study. All patients who had undergone both randomization and device surgery before this date were followed until study completion. We therefore report data on 681 patients enrolled between October 2009 and February 2013. Details of trial enrollment and follow-up are shown in Figure 1 . The baseline clinical and demographic characteristics of the patients were similar in the two groups (Table 1) .
DEVICE SURGERY AND PERIOPERATIVE ANTICOAGULATION
Preoperative bridging therapy was performed with the use of low-molecular-weight heparin (in 89.0% of patients), intravenous heparin (in 10.7%), or both (in 0.3%). Postoperative bridging therapy was performed with the use of low-molecularweight heparin (in 82.2% of patients), intravenous heparin (in 15.9%), or both (in 1.9%). The median INR on the day of surgery was 1.2 (interquartile range, 1.1 to 1.3) in the heparin-bridging group and 2.3 (interquartile range, 2.0 to 2.6) in the continued-warfarin group (P<0.001). There were no significant between-group differences in any other perioperative variables ( Table 2) . Surgery was postponed in eight patients in the continued-warfarin group because of a supratherapeutic INR on the day of surgery (mean [±SD] INR, 3.9±0.4). In the heparin-bridging group, surgery was postponed in three patients (P = 0.27); two patients had supratherapeutic INRs of 1.9 and 2.8, and bridging therapy in one patient had not been discontinued according to protocol.
PRIMARY OUTCOME
The primary outcome occurred in 12 of 343 patients (3.5%) in the continued-warfarin group as compared with 54 of 338 (16.0%) in the heparinbridging group (relative risk, 0.19; 95% confidence interval (CI), 0.10 to 0.36; P<0.001). There were significant differences in each of the three components of the primary outcome (Table 3) . Treatment effects were consistent in each of seven subgroups (Fig. 2) .
SECONDARY OUTCOMES
Secondary outcomes are shown in Table 3 . There were no embolic events in the heparin-bridging group. Two patients in the continued-warfarin group had embolic events; both patients had nonvalvular atrial fibrillation and a high risk of stroke as determined at enrollment according to the CHADS 2 score (an index of the risk of stroke among patients with atrial fibrillation, with scores ranging from 0 to 6 and higher scores indicating a greater risk of stroke). A stroke in the right occipital lobe occurred 2 days after surgery in an 89-year-old woman with a CHADS 2 score of 5 and an INR of 1.2 on the day of surgery. A transient ischemic attack occurred 2 days after surgery in an 88-year-old woman with a CHADS 2 score of 4 and an INR of 1.0 on the day of surgery. In both patients, the subtherapeutic INR was not intentional. There was one episode of cardiac tamponade requiring pericardiocentesis in the heparin-bridging group. Six patients in the heparin-bridging group (1.8%) and two in the continued-warfarin group (0.6%) had infections related to the device system (P = 0.17). In all eight patients, the infection necessitated complete system extraction. As compared with patients in the heparin-bridging group, those in the continued-warfarin group reported greater satisfaction with the management of their perioperative anticoagulation therapy, but there were no significant differences in quality of life or perioperative pain scores (Table S1 in the Supplementary Appendix).
DEATHS
There were four deaths, all occurring in the continued-warfarin group (P = 0.12). Three patients died before surgery: one patient died suddenly from (Table S4 and S5 in the Supplementary Appendix). Patients with hematomas had significant increases in perioperative pain and significant decreases in quality of life. Details of followup data for patients with hematomas are provided in the Supplementary Appendix.
DISCUSSION
In this large, randomized trial, we evaluated the safety of performing pacemaker or ICD surgery without interruption of warfarin therapy in patients requiring oral anticoagulation therapy. We found that this strategy is associated with a significantly lower rate of device-pocket hematoma, as compared with bridging therapy with heparin (3.5% vs. 16.0%). We also found that continued warfarin therapy, with a median INR of 2.3 (interquartile range, 2.0 to 2.6), was not associated with any major perioperative bleeding events and was associated with greater patient satisfaction. These results suggest that continuation of warfarin during pacemaker or ICD surgery may be preferable to bridging therapy with heparin, at least for patients like those enrolled in our trial. The significantly lower rate of device-pocket hematoma that we observed with continued warfarin may seem counterintuitive. One explanation that has been proposed is the concept of an "anticoagulant stress test." 9 That is, if patients undergo surgery while receiving full-dose anticoagulation therapy, any excessive bleeding will be detectable and appropriately managed while the wound is still open. In contrast, if bridging 
Secondary outcomes
Death from any cause -no. therapy with heparin is used, such bleeding may be apparent only when full-dose anticoagulation therapy is resumed postoperatively. 9 Our results are consistent with observations on bridging therapy in other situations. Siegal et al. 22 recently conducted a meta-analysis of the safety and efficacy of periprocedural bridging therapy, which included more than 12,000 patients in 34 studies, with only one randomized trial. The comparison groups in these studies included mostly patients in whom oral anticoagulation therapy was discontinued without bridging, with smaller numbers of patients in whom oral anticoagulation therapy was continued during surgery. The authors concluded that bridging with heparin leads to a risk of overall bleeding that is 5 times as high, and a risk of major bleeding that is 3.6 times as high, as the respective risks associated with no bridging therapy. The risk of thromboembolic events did not differ significantly between the two treatment strategies. 22 We specifically included patients with an annual risk of thromboembolic events of more than 5%, for whom complete discontinuation of anticoagulation therapy at the time of surgery might have been too risky. The findings of our trial are not directly relevant to patients with a lower risk of thromboembolic events (<5%), and it is possible that such patients may not require any anticoagulation or bridging therapy during the periprocedural period. Additional data from large, randomized trials are needed to better define the role of periprocedural bridging therapy with heparin.
Guidelines suggest that the continuation of warfarin at the time of minor dental, dermatologic, or ophthalmologic procedures is associated with an acceptable risk of bleeding. 6,21 Although not directly relevant, the results of our study are consistent with this recommendation, particularly since the bleeding risk is low with these other procedures, whereas the risk is increased with pacemaker or ICD surgery. 30 and hip and knee replacements. 29 However, additional randomized, controlled trials are needed in these areas. It should also be recognized that a strategy of continued warfarin is unlikely to be considered in major abdominal, cardiothoracic, or neurologic surgery.
Three oral anticoagulant agents -dabigatran, rivaroxaban, and apixaban -have been approved within the past few years for the prevention of stroke in patients with atrial fibrillation. [31] [32] [33] These agents have short half-lives, with maximal anticoagulant effects observed soon after oral intake and reduction of the effects soon after discontinuation. Whether it is better for patients to undergo surgery without interruption of these agents or with temporary cessation is currently unclear. The results of our study cannot be applied to patients receiving these agents.
One limitation of our trial is the subjectivity of the primary end point and the possibility that on occasion the team that was initially unaware of the treatment assignment became aware of the assignment and allowed biases to affect the assessment of primary end-point events. The most obvious potential situation for unblinding was among patients who were prescribed postoperative intravenous heparin. However, this treatment was used in only 17.8% of the patients, and the incidence of hematoma was similar among patients treated with postoperative intravenous heparin (16.1%) and those treated with postoperative low-molecular-weight heparin (16.6%). There is additional reassurance about the veracity of the blinding from the objective data showing that patients with hematomas had significant increases in perioperative pain and significant decreases in quality of life.
In conclusion, we investigated two approaches to performing pacemaker or ICD surgery in patients requiring long-term oral anticoagulation therapy. Patients were randomly assigned to undergo the planned operation with bridging anticoagulation therapy with heparin or to undergo the surgery without interruption of warfarin therapy. Patients who underwent surgery without interruption of warfarin therapy had a markedly reduced incidence of clinically significant devicepocket hematoma, as compared with those who received bridging therapy with heparin.
